About this data Sourced primarily from ClinicalTrials.gov — a listing isn't proof of safety or FDA approval.

Pipeline and clinical trial information here comes primarily from ClinicalTrials.gov. A listing on ClinicalTrials.gov means a study has been registered — not that a treatment is proven safe, effective, or FDA-approved. Investigational treatments may never be approved. Who can join a trial is decided only by that trial's own study team.

Not yet reported

Linagliptin

Company: Sun Yat-sen University
Mechanism: Mechanism not yet reported
Route: Route not yet reported
Recruiting trials: 6 recruiting

Efficacy results: Not yet reported

Find a Clinical Trial Near Me

6 recruiting studies currently listed on ClinicalTrials.gov.

Data source: ClinicalTrials.gov · trial data as of Oct 17, 2026

Trial details

Recruiting NCT NCT04670666

Efficacy and Safety of Madalena Association in the Treatment of Type II Diabetes Mellitus

Not yet reported EMS 270 participants Est. completion 2027-06 1 site Stand-alone

Type 2 diabetes
View official trial listing →
Recruiting NCT NCT06095492

Effect of Empagliflozin vs Linagliptin on Glycemic Outcomes,Renal Outcomes & Body Composition in Renal Transplant Recipients With Diabetes Mellitus

Not yet reported Medanta, The Medicity, India 200 participants Est. completion 2025-12-01 1 site

Other conditions: Kidney Transplant; Complications, Diabetes Mellitus
View official trial listing →
Recruiting NCT NCT06449833

Effect of Henagliflozein on Hepatic Fat Content in Patients With T2DM and NAFLD

Not yet reported Zhujiang Hospital 100 participants Est. completion 2026-11 1 site

Type 2 diabetesMASLD
View official trial listing →
Recruiting NCT NCT06862739

Glycemic Control With Triple Pathway Approach Through Empagliflozin, Linagliptin and Metformin Combination

Not yet reported Nabiqasim Industries (Pvt) Ltd 800 participants Est. completion 2026-06-30 2 sites

Other conditions: Diabetes Mellitus, Type 2 DM
View official trial listing →
Recruiting NCT NCT07019012

Cofrogliptin Once Every 2 Weeks as Add-on Therapy to Metformin and Dapagliflozin Versus Daily Linagliptin in Patients With Type 2 Diabetes.

Not yet reported Huazhong University of Science and Technology 170 participants Est. completion 2026-12-30 2 sites

Type 2 diabetes
View official trial listing →
Recruiting NCT NCT07442006

Glycemic Variability of Combination Therapies in T2DM

Not yet reported JW Pharmaceutical 178 participants Est. completion 2027-03-31 1 site

Type 2 diabetes
View official trial listing →
Completed NCT NCT00309608

Efficacy and Safety of BI 1356 BS (Linagliptin) in Combination With Metformin in Patients With type2 Diabetes

Not yet reported Boehringer Ingelheim 333 participants 48 sites Stand-alone

Type 2 diabetes
View official trial listing →
Completed NCT NCT00328172

Efficacy and Safety of 3 Doses of BI1356 (Linagliptin) in Type 2 Diabetes Patients

Not yet reported Boehringer Ingelheim 302 participants 71 sites

Type 2 diabetes
View official trial listing →
Completed NCT NCT00601250

Efficacy and Safety of B I1356 (Linagliptin) vs. Placebo Added to Metformin Background Therapy in Patients With Type 2 Diabetes

Not yet reported Boehringer Ingelheim 701 participants 82 sites Stand-alone

Type 2 diabetes
View official trial listing →
Completed NCT NCT00602472

BI 1356 (Linagliptin) in Combination With Metformin and a Sulphonylurea in Type 2 Diabetes

Not yet reported Boehringer Ingelheim 1058 participants 100 sites Stand-alone

Type 2 diabetes
View official trial listing →
Completed NCT NCT00621140

Efficacy and Safety of BI 1356 (Linagliptin) Versus Placebo in Type 2 Diabetic Patients With Insufficient Glycemic Control

Not yet reported Boehringer Ingelheim 503 participants 69 sites Stand-alone

Type 2 diabetes
View official trial listing →
Completed NCT NCT00622284

Efficacy and Safety of BI 1356 in Combination With Metformin in Patients With Type 2 Diabetes

Not yet reported Boehringer Ingelheim 1560 participants 221 sites

Type 2 diabetes
View official trial listing →
Completed NCT NCT00641043

Efficacy vs Placebo as Initial Combination Therapy With Pioglitazone

Not yet reported Boehringer Ingelheim 389 participants 43 sites Stand-alone

Type 2 diabetes
View official trial listing →
Completed NCT NCT00654381

Japanese P III vs Voglibose and Placebo

Not yet reported Boehringer Ingelheim 561 participants 47 sites

Type 2 diabetes
View official trial listing →
Completed NCT NCT00716092

The Effect of Linagliptin (BI 1356) on 24h-glucose Control and Various Biomarkers in Type 2 Diabetic Patients

Not yet reported Boehringer Ingelheim 121 participants 3 sites Stand-alone

Type 2 diabetes
View official trial listing →
Completed NCT NCT00736099

Safety and Efficacy of Linagliptin (BI 1356) as Monotherapy or in Combination in Type 2 DM

Not yet reported Boehringer Ingelheim 2122 participants 232 sites Stand-alone

Type 2 diabetes
View official trial listing →
Completed NCT NCT00740051

A Randomised, db, Placebo-controlled Study of BI 1356 for 18 Weeks Followed by a 34 Week Double-blind Extension Period (Placebo Patients Switched to Glimepiride) in Type 2 Diabetic Patients for Whom Treatment With Metformin is Inappropriate

Not yet reported Boehringer Ingelheim 227 participants 53 sites Stand-alone

Type 2 diabetes
View official trial listing →
Completed NCT NCT00798161

Safety and Efficacy of Linagliptin (BI 1356) Plus Metformin in Type 2 Diabetes, Factorial Design

Not yet reported Boehringer Ingelheim 857 participants 138 sites

Type 2 diabetes
View official trial listing →
Completed NCT NCT00800683

Safety and Efficacy in Type 2 Diabetic Patients With Severe Chronic Renal Impairment, 5 mg BI 1356 (Linagliptin) vs. Placebo, Insulin Background Inclusive

Not yet reported Boehringer Ingelheim 133 participants 53 sites

Type 2 diabetes
View official trial listing →
Completed NCT NCT00819091

Randomized, Double-blind (db), Placebo-controlled 18 Week Study of Linagliptin (BI 1356) in Type 2 Diabetic Patients With Insufficient Glycaemic Control on a Sulfonylurea Drug

Not yet reported Boehringer Ingelheim 245 participants 45 sites

Type 2 diabetes
View official trial listing →
Completed NCT NCT00915772

Treatment of Type 2 Diabetes With Linagliptin 2.5 mg Bid + Metformin 500 or 1000 mg Bid and Metformin 1000 mg Bid

Not yet reported Boehringer Ingelheim 567 participants 112 sites Stand-alone

Type 2 diabetes
View official trial listing →
Completed NCT NCT00935220

Pharmacokinetics and Pharmacodynamics Trial With Linagliptin (BI 1356) 5mg in African American Type 2 Diabetic Patients

Not yet reported Boehringer Ingelheim 41 participants 6 sites Stand-alone

Type 2 diabetes
View official trial listing →
Completed NCT NCT00954447

Efficacy and Safety of Linagliptin in Combination With Insulin in Patients With Type 2 Diabetes

Not yet reported Boehringer Ingelheim 1263 participants 169 sites Stand-alone

Type 2 diabetes
View official trial listing →
Completed NCT NCT00996658

Linagliptin Versus Placebo in Type 2 Diabetic Patients With Inadequate Glycaemic Control on Metformin in Combination With Pioglitazone

Not yet reported Boehringer Ingelheim 278 participants 52 sites Stand-alone

Type 2 diabetes
View official trial listing →
Completed NCT NCT01012037

Linagliptin 2.5 mg Twice Daily Versus 5 mg Once Daily as add-on Therapy to Twice Daily Metformin in Type 2 Diabetes

Not yet reported Boehringer Ingelheim 491 participants 84 sites Stand-alone

Type 2 diabetes
View official trial listing →
Completed NCT NCT01084005

Efficacy and Safety of Linagliptin in Elderly Patients With Type 2 Diabetes

Not yet reported Boehringer Ingelheim 241 participants 34 sites Stand-alone

Type 2 diabetes
View official trial listing →
Completed NCT NCT01087502

Safety and Efficacy of Linagliptin in Type-2-diabetes Mellitus Patients With Moderate to Severe Renal Impairment

Not yet reported Boehringer Ingelheim 241 participants 52 sites Stand-alone

Type 2 diabetes
View official trial listing →
Completed NCT NCT01183013

30 Week Parallel Group Comparison Study of Linagliptin + Pioglitazone (5+15, 5+30 and 5+45 mg) qd Versus Respective Monotherapies, Followed by a Comparison of 5mg+30mg and 5mg+45mg Versus Respective Monotherapies in Type 2 Diabetes for up to 54 Weeks

Not yet reported Boehringer Ingelheim 936 participants Est. completion 2013-02 132 sites Stand-alone

Type 2 diabetes
View official trial listing →
Completed NCT NCT01189201

Rel. BA of Empagliflozin (BI 10773)/Linagliptin FDC Tbl, Comparison With Mono-components, With a Second FDC Tablet and Influence of Food

Not yet reported Boehringer Ingelheim 42 participants 1 site Stand-alone

Other conditions: Healthy
View official trial listing →
Completed NCT NCT01194830

Efficacy and Safety of Linagliptin (BI 1356) in Black/African Americans With Type 2 Diabetes With a MTT Sub-study

Not yet reported Boehringer Ingelheim 234 participants Est. completion 2011-10 93 sites

Type 2 diabetes
View official trial listing →
Completed NCT NCT01204294

Comprehensive Add on Study in Japan

Not yet reported Boehringer Ingelheim 574 participants Est. completion 2012-01 43 sites Stand-alone

Type 2 diabetes
View official trial listing →
Completed NCT NCT01214239

Efficacy and Safety Study of Linagliptin (5 mg Administered Orally Once Daily) Over 24 Weeks, in Drug naïve or Previously Treated Type 2 Diabetic Patients With Insufficient Glycaemic Control

Not yet reported Boehringer Ingelheim 300 participants 19 sites Stand-alone

Type 2 diabetes
View official trial listing →
Completed NCT NCT01215097

Efficacy and Safety Study of Linagliptin (5 mg Administered Orally Once Daily) Over 24 Weeks in Type 2 Diabetic Patients With Insufficient Glycaemic Control Despite Metformin Therapy

Not yet reported Boehringer Ingelheim 306 participants Est. completion 2012-04 19 sites Stand-alone

Type 2 diabetes
View official trial listing →
Completed NCT NCT01216397

Relative Bioavailability of Two Different Batches of a Linagliptin / Metformin Combination Tablet in Healthy Volunteers

Not yet reported Boehringer Ingelheim 40 participants 1 site Stand-alone

Other conditions: Healthy
View official trial listing →
Completed NCT NCT01243424

CAROLINA: Cardiovascular Outcome Study of Linagliptin Versus Glimepiride in Patients With Type 2 Diabetes

Not yet reported Boehringer Ingelheim 6103 participants Est. completion 2018-08-21 613 sites Stand-alone

Type 2 diabetes
View official trial listing →
Completed NCT NCT01276327

Bioequivalence of a Fixed Dose Combination Tablet Linagliptin/Pioglitazone Compared With Its Mono-components

Not yet reported Boehringer Ingelheim 64 participants 1 site Stand-alone

Other conditions: Healthy
View official trial listing →
Completed NCT NCT01342484

Finding a Safe and Effective Dose of Linagliptin in Pediatric Patients With Type 2 Diabetes

Not yet reported Boehringer Ingelheim 40 participants Est. completion 2016-02 25 sites Stand-alone

Type 2 diabetes
View official trial listing →
Completed NCT NCT01383356

Comparison of the Bioavailability of Metformin Between Medium Dose Linagliptin/Metformin Tablets and Medium Dose Glucophage Tablet Given With Linagliptin Tablet

Not yet reported Boehringer Ingelheim 58 participants Est. completion 2011-12 1 site Stand-alone

Type 2 diabetes
View official trial listing →
Completed NCT NCT01422876

Efficacy and Safety of Empagliflozin (BI 10773) / Linagliptin (BI 1356) Fixed Dose Combination in Treatment naïve and Metformin Treated Type 2 Diabetes Patients

Not yet reported Boehringer Ingelheim 1405 participants Est. completion 2013-09 211 sites Stand-alone

Type 2 diabetes
View official trial listing →
Completed NCT NCT01438814

Linagliptin in Combination With Metformin in Treatment Naive Patients With Type 2 Diabetes Mellitus and Insufficient Glycaemic Control

Not yet reported Boehringer Ingelheim 689 participants Est. completion 2013-03 90 sites Stand-alone

Type 2 diabetes
View official trial listing →
Completed NCT NCT01512979

Linagliptin and Metformin Versus Linagliptin in Newly Diagnosed, Untreated Type 2 Diabetes

Not yet reported Boehringer Ingelheim 316 participants Est. completion 2013-04 82 sites Stand-alone

Type 2 diabetes
View official trial listing →
Completed NCT NCT01540487

Pharmacokinetics of Fixed Dose Combination (FDC) Tablets of Linagliptin /Metformin

Not yet reported Boehringer Ingelheim 48 participants Est. completion 2012-06 1 site Stand-alone

Other conditions: Healthy
View official trial listing →
Status unknown NCT NCT01547104

Effect of Linagliptin in Comparison With Glimepiride as Add on to Metformin on Postprandial Beta Cell Function, Postprandial Metabolism and Oxidative Stress in Patients With Type 2 Diabetes Mellitus

Not yet reported Marcus Borchert 40 participants Est. completion 2012-10 1 site Stand-alone

Type 2 diabetes
View official trial listing →
Completed NCT NCT01581931

Bioequivalence of Metformin Under Fed Conditions After Administration of Linagliptin / Metformin Fixed Dose Combination Tablet and Single Tablets

Not yet reported Boehringer Ingelheim 32 participants Est. completion 2012-06 1 site Stand-alone

Other conditions: Healthy
View official trial listing →
Completed NCT NCT01617824

Rapid Effects Linagliptin on Monocyte Polarization and Endothelial Progenitor Cells in Type 2 Diabetes

Not yet reported University of Padova 45 participants Est. completion 2014-12 1 site Stand-alone

Type 2 diabetes Other conditions: Chronic Renal Failure
View official trial listing →
Completed NCT NCT01650259

Long-term Daily Use of Trazenta® Tablets in Patients With Type 2 Diabetes Mellitus

Boehringer Ingelheim 4876 participants Est. completion 2017-09-14 1 site

Type 2 diabetes
View official trial listing →
Completed NCT NCT01677104

The Microvascular Function of GLP-1 and Its Analogues

Not yet reported Katarina Kos 63 participants Est. completion 2014-07 1 site

Type 2 diabetes Other conditions: Obesity
View official trial listing →
Completed NCT NCT01703286

Trial to Assess the Influence of 4 Weeks' Treatment With Linagliptin as Compared to Glimepiride and Placebo on Endothelial Function in Patients With Type 2 Diabetes Using FMD (Flow-Mediated Vasodilation)

Not yet reported Boehringer Ingelheim 42 participants Est. completion 2014-01 1 site Stand-alone

Type 2 diabetes
View official trial listing →
Completed NCT NCT01707147

A Non Interventional Study to Monitor the Safety and Effectiveness of Trajenta (Linagliptin, 5 mg, q.d) in Korean Patients With Type 2 Diabetes Mellitus

Boehringer Ingelheim 3219 participants Est. completion 2017-07-11 1 site

Type 2 diabetes
View official trial listing →
Completed NCT NCT01708902

Study to Compare the Efficacy and Safety of Administration of the Fix Dose Combination of Linagliptin Plus Metformin in Drug naïve Type 2 Patients

Not yet reported Boehringer Ingelheim 876 participants Est. completion 2014-04 56 sites Stand-alone

Type 2 diabetes
View official trial listing →
Completed NCT NCT01734785

Safety and Efficacy of the Combination of Empagliflozin and Linagliptin Compared to Linagliptin Alone Over 24 Weeks in Patients With Type 2 Diabetes

Not yet reported Boehringer Ingelheim 607 participants Est. completion 2015-03-23 90 sites Stand-alone

Type 2 diabetes
View official trial listing →
Completed NCT NCT01767389

Glucagon-like Peptide (GLP) Utilization and Safety

GlaxoSmithKline 1 participants Est. completion 2013-12

Type 2 diabetes
View official trial listing →
Completed NCT NCT01778049

Linagliptin as Add on Therapy to Empagliflozin 10 mg or 25 mg With Background Metformin in Patient With Type 2 Diabetes

Not yet reported Boehringer Ingelheim 708 participants Est. completion 2015-03 114 sites Stand-alone

Type 2 diabetes
View official trial listing →
Completed NCT NCT01792518

MARLINA - T2D : Efficacy, Safety & Modification of Albuminuria in Type 2 Diabetes Subjects With Renal Disease With LINAgliptin

Not yet reported Boehringer Ingelheim 360 participants Est. completion 2015-12 74 sites Stand-alone

Type 2 diabetes
View official trial listing →
Terminated NCT NCT01826370

Linagliptin Among Filipino Patients With Type 2 Diabetes Mellitus

Boehringer Ingelheim 678 participants Est. completion 2013-10 51 sites

Type 2 diabetes
View official trial listing →
Completed NCT NCT01835678

Effects of Linagliptin on Renal Endothelium Function in Patients With Type 2 Diabetes.

Not yet reported University of Erlangen-Nürnberg Medical School 65 participants Est. completion 2014-04 2 sites

Other conditions: Type 2-diabetes
View official trial listing →
Completed NCT NCT01845077

Relative Bioavailability of 2 Fixed Dose Combinations of Linagliptin/Metformin Compared With Single Tablets

Not yet reported Boehringer Ingelheim 72 participants Est. completion 2013-08 1 site Stand-alone

Other conditions: Healthy
View official trial listing →
Terminated NCT NCT01888796

Diastolic Dysfunction in Patients With Type 2 Diabetes Mellitus

Not yet reported RWTH Aachen University 8 participants Est. completion 2014-12 1 site

Type 2 diabetes Other conditions: Left Ventricular Diastolic Dysfunction
View official trial listing →
Completed NCT NCT01897532

Cardiovascular and Renal Microvascular Outcome Study With Linagliptin in Patients With Type 2 Diabetes Mellitus (CARMELINA)

Not yet reported Boehringer Ingelheim 6991 participants Est. completion 2018-01-18 649 sites Stand-alone

Type 2 diabetes
View official trial listing →
Completed NCT NCT01903070

Effects of Linagliptin on Active GLP-1 Concentrations in Subjects With Renal Impairment

Not yet reported Profil Institut für Stoffwechselforschung GmbH 99 participants Est. completion 2016-04 1 site Stand-alone

Other conditions: Diabetes Mellitus
View official trial listing →
Completed NCT NCT01903356

A Regulatory Requirement Non Interventional Study to Monitor Safety and Effectiveness of Trajenta Duo in Type 2 Diabetes Patients in Korea

Boehringer Ingelheim 724 participants Est. completion 2017-06-10 1 site

Type 2 diabetes
View official trial listing →
Terminated NCT NCT01943019

Linagliptin in Schizophrenia Patients

Not yet reported Monash University 1 participants Est. completion 2018-08 1 site Stand-alone

Other conditions: Schizophrenia
View official trial listing →
Completed NCT NCT01947153

Two-way Crossover Study in Healthy Male and Female Subjects to Evaluate the Bioequivalence of Jentadueto®.

Not yet reported Boehringer Ingelheim 36 participants Est. completion 2014-01 1 site Stand-alone

Other conditions: Healthy
View official trial listing →
Completed NCT NCT01968044

A Phase IIIb Study to Evaluate the Safety and Efficacy of Gemigliptin in Type 2 Diabetes Mellitus Patients With Moderate or Severe Renal Impairment(GUARD Study)

Not yet reported LG Life Sciences 132 participants Est. completion 2015-10 1 site

Other conditions: Type 2 DM Patients With Moderate or Severe Renal Impairment
View official trial listing →
Completed NCT NCT01969084

The Effect of Linagliptin on Mitochondrial and Endothelial Function

Not yet reported Beth Israel Deaconess Medical Center 45 participants Est. completion 2016-07 1 site Stand-alone

Other conditions: Type II Diabetes Mellitus
View official trial listing →
Status unknown NCT NCT01974544

Prevention and Treatment Of Diabetes Complications With Gastric Surgery or Intensive Medicines

Not yet reported Pontificia Universidad Catolica de Chile 150 participants Est. completion 2016-12 1 site Stand-alone

Type 2 diabetes
View official trial listing →
Completed NCT NCT02004366

Linagliptin Inpatient Trial

Not yet reported Emory University 295 participants Est. completion 2017-03 5 sites Stand-alone

Type 2 diabetes
View official trial listing →
Completed NCT NCT02015299

Off taRget Effects of Linagliptin monothErapy on Arterial Stiffness in Early Diabetes

Not yet reported dr. DJ Mulder 45 participants Est. completion 2016-03 1 site Stand-alone

Type 2 diabetes
View official trial listing →
Completed NCT NCT02041234

Roux-en-Y Gastric Bypass for BMI 27-32 Type 2 Diabetes Versus Best Medical Treatment

Not yet reported Khoo Teck Puat Hospital 40 participants Est. completion 2022-06 1 site

Other conditions: Type II Diabetes in Subjects BMI 27 to 32
View official trial listing →
Completed NCT NCT02061969

ADA Linagliptin in Long Term Care

Not yet reported Emory University 140 participants Est. completion 2017-04-10 4 sites Stand-alone

Other conditions: Diabetes
View official trial listing →
Terminated NCT NCT02072096

A Comparison of Two Treatment Strategies in Older Participants With Type 2 Diabetes Mellitus (T2DM)

Not yet reported Eli Lilly and Company 192 participants Est. completion 2015-10 34 sites Added to GLP-1

Type 2 diabetes
View official trial listing →
Terminated NCT NCT02077309

Effect of Linagliptin on Vascular Inflammation in Patients With Type 2 Diabetes Mellitus

Not yet reported RWTH Aachen University 4 participants Est. completion 2015-11 2 sites

Type 2 diabetes Other conditions: Vascular Inflammation, Plaque Morphology
View official trial listing →
Completed NCT NCT02084056

Bioequivalence of a FDC Tablet of Linagliptin/Metformin (2.5mg/1000mg) Extended Release in Healthy Subjects.

Not yet reported Boehringer Ingelheim 74 participants Est. completion 2014-07 1 site Stand-alone

Other conditions: Healthy
View official trial listing →
Completed NCT NCT02084082

Bioequivalence of a FDC Tablet of Linagliptin/Metformin (5mg/1000mg) Extended Release in Healthy Subjects

Not yet reported Boehringer Ingelheim 68 participants Est. completion 2014-07 1 site Stand-alone

Other conditions: Healthy
View official trial listing →
Completed NCT NCT02092597

Safety Evaluation of Adverse Reactions in Diabetes

Not yet reported Charles University, Czech Republic 42 participants Est. completion 2016-09 1 site

Type 2 diabetes
View official trial listing →
Status unknown NCT NCT02097342

Effect of Linagliptin on Insulin Sensitivity and Pancreatic Beta Cell Function in Patients With Type 2 Diabetes Mellitus

Not yet reported Post Graduate Institute of Medical Education and Research, Chandigarh 30 participants Est. completion 2015-01 1 site Stand-alone

Type 2 diabetes Other conditions: Insulin Sensitivity/Resistance
View official trial listing →
Completed NCT NCT02106104

Renal Effects of DPP-4 Inhibitor Linagliptin in Type 2 Diabetes

Not yet reported Amsterdam UMC, location VUmc 48 participants Est. completion 2016-04 1 site Stand-alone

Type 2 diabetes
View official trial listing →
Completed NCT NCT02121509

Bioequivalence of a FDC Tablet of Linagliptin/Metformin (2.5mg/750mg) Extended Release in Healthy Subjects

Not yet reported Boehringer Ingelheim 74 participants Est. completion 2014-07 1 site Stand-alone

Other conditions: Healthy
View official trial listing →
Completed NCT NCT02138097

Oral and Non-insulin Injected Hypoglycemic Therapy Utilization Patterns

Boehringer Ingelheim 615067 participants Est. completion 2014-08 1 site

Type 2 diabetes
View official trial listing →
Completed NCT NCT02140645

Ascertainment of EMR-based Clinical Covariates Among Patients Receiving Oral and Non-insulin Injected Hypoglycemic Therapy

Boehringer Ingelheim 166613 participants Est. completion 2015-03 1 site

Type 2 diabetes
View official trial listing →
Completed NCT NCT02172222

Relative Bioavailability of BI 10773 and Linagliptin in Healthy Male Volunteers

Not yet reported Boehringer Ingelheim 16 participants Stand-alone

Other conditions: Healthy
View official trial listing →
Completed NCT NCT02173639

Bioavailability of Combination Tablet BI 1356/Metformin Compared With Single BI 1356 and Metformin Administered Together to Healthy Male and Female Subjects

Not yet reported Boehringer Ingelheim 20 participants

Other conditions: Healthy
View official trial listing →
Completed NCT NCT02173652

Pharmacokinetics and Pharmacodynamics of Multiple 5 mg Doses of BI 1356 p.o. Given Once Daily Compared to Multiple 2.5 mg Doses Given Twice Daily in Healthy Male and Female Volunteers

Not yet reported Boehringer Ingelheim 16 participants

Other conditions: Healthy
View official trial listing →
Completed NCT NCT02173665

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Rising Oral Doses of BI 1356 BS Administered to Healthy Male Subjects

Not yet reported Boehringer Ingelheim 64 participants

Other conditions: Healthy
View official trial listing →
Completed NCT NCT02175394

Effect of Multiple BI 1356 Doses of on the Multiple-dose Pharmacokinetics of a Combination of Ethinylestradiol and Levonorgestrel in Healthy Female Premenopausal Subjects

Not yet reported Boehringer Ingelheim 18 participants

Other conditions: Healthy
View official trial listing →
Completed NCT NCT02180334

The Effect of Combination of Mosapride and DPP-4 Inhibitor on Plasma Concentration of Incretin Hormones

Not yet reported Seoul National University Hospital 12 participants Est. completion 2015-04 1 site Stand-alone

Type 2 diabetes
View official trial listing →
Completed NCT NCT02180503

Relative Bioavailability of 1 mg and 10 mg BI 1356 BS as Powder in the Bottle (PIB) to 1 mg and 10 mg BI 1356 BS as Tablets as Single Oral Administration in Healthy Male Volunteers Including the Influence of Food on the Bioavailability of 10 mg BI 1356 BS

Not yet reported Boehringer Ingelheim 24 participants

Other conditions: Healthy
View official trial listing →
Completed NCT NCT02183298

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Rising Doses of BI 1356 BS in Healthy Male Volunteers

Not yet reported Boehringer Ingelheim 36 participants

Other conditions: Healthy
View official trial listing →
Completed NCT NCT02183311

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Rising Oral Doses and Multiple Rising Oral Doses of BI 1356 BS in Healthy Male Volunteers

Not yet reported Boehringer Ingelheim 56 participants

Other conditions: Healthy
View official trial listing →
Completed NCT NCT02183324

BI 1356 BS in Japanese Patients With Type 2 Diabetes Mellitus

Not yet reported Boehringer Ingelheim 72 participants

Type 2 diabetes
View official trial listing →
Completed NCT NCT02183337

Bioavailability of BI 1356 With and Without Co-administration of Pioglitazone and the Bioavailability of Pioglitazone With and Without Coadministration of BI 1356 in Healthy Male and Female Volunteers

Not yet reported Boehringer Ingelheim 20 participants

Other conditions: Healthy
View official trial listing →
Completed NCT NCT02183350

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BI 1356 BS in Patients With Type 2 Diabetes

Not yet reported Boehringer Ingelheim 47 participants

Type 2 diabetes
View official trial listing →
Completed NCT NCT02183363

Bioavailability of BI 1356 After Single Oral Administration Given as Different Tablet Formulation in Healthy Male Volunteers

Not yet reported Boehringer Ingelheim 24 participants

Other conditions: Healthy
View official trial listing →
Completed NCT NCT02183376

Pharmacokinetics and Pharmacodynamics of BI 1356 in Subjects With Different Degrees of Liver Impairment as Compared to Healthy Subjects

Not yet reported Boehringer Ingelheim 33 participants

Other conditions: Hepatic Insufficiency
View official trial listing →
Completed NCT NCT02183389

Bioavailability of Warfarin After Coadministration With Multiple Doses of BI 1356 Compared to the Bioavailability of Warfarin Alone in Healthy Male Volunteers

Not yet reported Boehringer Ingelheim 18 participants

Other conditions: Healthy
View official trial listing →
Completed NCT NCT02183402

Pharmacokinetics, Safety and Tolerability of Digoxin With or Without Co-administration of BI 1356 in Healthy Volunteers

Not yet reported Boehringer Ingelheim 20 participants

Other conditions: Healthy
View official trial listing →
Completed NCT NCT02183415

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BI 1356 BS as Tablet in Patients With Type 2 Diabetes

Not yet reported Boehringer Ingelheim 77 participants

Type 2 diabetes
View official trial listing →
Completed NCT NCT02183428

Bioavailability of BI 1356 and Glyburide in Healthy Male and Female Volunteers

Not yet reported Boehringer Ingelheim 20 participants

Other conditions: Healthy
View official trial listing →
Completed NCT NCT02183441

Bioavailability of BI 1356 After Co-administration With Ritonavir Compared to the Bioavailability of BI 1356 Alone in Healthy Male Volunteers

Not yet reported Boehringer Ingelheim 12 participants

Other conditions: Healthy
View official trial listing →
Completed NCT NCT02183467

Effect of BI 1356 as Single Dose on the QT Interval in Healthy Female and Male Subjects

Not yet reported Boehringer Ingelheim 44 participants

Other conditions: Healthy
View official trial listing →
Completed NCT NCT02183480

Dose Proportionality of Different Dose Strengths of Linagliptin Tablets After Oral Administration to Healthy Male and Female Volunteers

Not yet reported Boehringer Ingelheim 12 participants Stand-alone

Other conditions: Healthy
View official trial listing →
Completed NCT NCT02183493

Bioavailability of BI 1356 Administered With and Without Food to Healthy Male and Female Subjects

Not yet reported Boehringer Ingelheim 32 participants

Other conditions: Healthy
View official trial listing →
Completed NCT NCT02183506

Bioavailability of BI 1356 BS and Metformin After Co-administration Compared to the Bioavailability of BI 1356 BS Alone and Metformin Alone in Healthy Male Volunteers

Not yet reported Boehringer Ingelheim 16 participants

Other conditions: Healthy
View official trial listing →
Completed NCT NCT02183532

Pharmacokinetics of Single and Multiple Oral Doses of BI 1356 in Healthy Chinese Volunteers

Not yet reported Boehringer Ingelheim 12 participants

Other conditions: Healthy
View official trial listing →
Completed NCT NCT02183584

Study to Evaluate the Effect of Multiple Doses of Rifampicin on the Multiple-dose Pharmacokinetics of Linagliptin in Healthy Volunteers

Not yet reported Boehringer Ingelheim 16 participants Stand-alone

Other conditions: Healthy
View official trial listing →
Completed NCT NCT02183610

Investigation of the Metabolism and Pharmacokinetics of 10 mg [14C] BI 1356 Administered Orally Compared to 5 mg [14C] BI 1356 Administered Intravenously in Healthy Male Volunteers

Not yet reported Boehringer Ingelheim 12 participants

Other conditions: Healthy
View official trial listing →
Completed NCT NCT02183623

The Effect of Multiple Oral Doses of BI 1356 BS on Pharmacokinetics, Safety and Tolerability of Multiple Oral Doses of Simvastatin and on the Pharmacokinetics of Its Metabolite Simvastatin Acid in Healthy Male Volunteers

Not yet reported Boehringer Ingelheim 20 participants

Other conditions: Healthy
View official trial listing →
Completed NCT NCT02183636

Relative Bioavailability of Two Fixed Dose Combination Tablets of Linagliptin/Pioglitazone Compared With Single Linagliptin and Pioglitazone Tablets Administered Together to Healthy Male and Female Subjects

Not yet reported Boehringer Ingelheim 39 participants Stand-alone

Other conditions: Healthy
View official trial listing →
Completed NCT NCT02191228

Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Single and Multiple Doses of Linagliptin Tablets in Patients With Different Degrees of Renal Impairment in Comparison to Subjects With Normal Renal Function

Not yet reported Boehringer Ingelheim 51 participants Stand-alone

Other conditions: Renal Insufficiency
View official trial listing →
Completed NCT NCT02197078

Active Surveillance Research Program for the Assessment of the Safety and the Effectiveness of Linagliptin

Boehringer Ingelheim 189426 participants Est. completion 2019-02-26 1 site

Type 2 diabetes
View official trial listing →
Completed NCT NCT02212782

the Pharmacokinetic Profiles of Linagliptin With DW1029M

Not yet reported Dong Wha Pharmaceutical Co. Ltd. 12 participants Est. completion 2015-01 1 site Stand-alone

Other conditions: Healthy
View official trial listing →
Completed NCT NCT02220647

Bioequivalence of a 2.5 mg Linagliptin / 850 mg Metformin Fixed Dose Combination Tablet Compared With Single Linagliptin 2.5 mg and Metformin 850 mg Tablets in Healthy Volunteers

Not yet reported Boehringer Ingelheim 96 participants Stand-alone

Other conditions: Healthy
View official trial listing →
Completed NCT NCT02221401

Bioequivalence of a Linagliptin / Metformin Fixed-dose Combination (FDC) Tablet Compared With Single Linagliptin and Metformin Tablets Administered Together in Healthy Volunteers

Not yet reported Boehringer Ingelheim 96 participants Stand-alone

Other conditions: Healthy
View official trial listing →
Completed NCT NCT02221414

Bioequivalence of a 2.5 mg Linagliptin / 500 mg Metformin Fixed Dose Combination Tablet Compared With Single Linagliptin 2.5 mg and Metformin 500 mg Tablets Administered Together in Healthy Volunteers

Not yet reported Boehringer Ingelheim 95 participants Stand-alone

Other conditions: Healthy
View official trial listing →
Completed NCT NCT02223026

Relative Bioavailability of a Linagliptin+Metformin Fixed Dose Combination Tablet Administered With and Without Food to Healthy Male and Female Subjects

Not yet reported Boehringer Ingelheim 32 participants Stand-alone

Other conditions: Healthy
View official trial listing →
Completed NCT NCT02240680

Linagliptin as Add on to Basal Insulin in the Elderly

Not yet reported Boehringer Ingelheim 302 participants Est. completion 2017-04-25 145 sites Stand-alone

Type 2 diabetes
View official trial listing →
Terminated NCT NCT02244164

Pathophysiological Study of the Increase in Pancreatic Volume in Type 2 Diabetes Treatments.

Not yet reported Erasme University Hospital 5 participants Est. completion 2023-02-13 1 site

Type 2 diabetes Other conditions: Incretinomimetics, Pancreas
View official trial listing →
Status unknown NCT NCT02280174

Effect of Linagliptin on TRL Metabolism

Not yet reported Ministry of Public Health, Argentina 20 participants Est. completion 2016-10 1 site Stand-alone

Type 2 diabetes
View official trial listing →
Completed NCT NCT02312427

DPP-4 Inhibitor and Serum BNP Level of Diabetic Patients With Congestive Heart Failure

Not yet reported Mitsui Memorial Hospital 10 participants Est. completion 2016-03 1 site Stand-alone

Heart failure Other conditions: Diabetes Mellitus
View official trial listing →
Completed NCT NCT02350478

Effects of Linagliptin on Endothelial Function

Not yet reported Medical University of Graz 49 participants Est. completion 2017-03 1 site

Type 2 diabetesCardiovascular disease
View official trial listing →
Completed NCT NCT02372630

The Effect of LINAGLIPTIN on Inflammation, Oxidative Stress and Insulin Resistance in Obese Type 2 Diabetes Subjects

Not yet reported University at Buffalo 40 participants Est. completion 2018-05-01 1 site

Type 2 diabetes
View official trial listing →
Completed NCT NCT02376075

Effects of Linagliptin on Endothelial- , Renal-, and Retinal Function in Patients With Hypertension and Albuminuria

Not yet reported ikfe-CRO GmbH 43 participants Est. completion 2014-09 1 site

Other conditions: Arterial Hypertension, Albuminuria
View official trial listing →
Completed NCT NCT02401880

Effects of Linagliptin in Addition to Empagliflozin on Islet Cell Physiology

Not yet reported Profil Institut für Stoffwechselforschung GmbH 89 participants Est. completion 2015-12 2 sites

Type 2 diabetes
View official trial listing →
Status unknown NCT NCT02429232

A One-year Randomized Controlled Trial Evaluating the Impact of Pioglitazone Versus Linagliptin on Bone Turnover Markers

Not yet reported National Taiwan University Hospital 160 participants Est. completion 2017-12

Other conditions: Osteoporosis, Diabetes Mellitus
View official trial listing →
Completed NCT NCT02442817

Linagliptin and Mesenchymal Stem Cells: A Pilot Study

Not yet reported University of Nevada, Reno 10 participants Est. completion 2018-03-02 1 site

Other conditions: Schizophrenia
View official trial listing →
Completed NCT NCT02453555

Empagliflozin Add on to Linagliptin Study in Japanese Patient With Type 2 Diabetes Mellitus

Not yet reported Boehringer Ingelheim 275 participants Est. completion 2017-03-27 40 sites Stand-alone

Type 2 diabetes
View official trial listing →
Completed NCT NCT02467478

Linagliptin's Effect on CD34+ Stem Cells

Not yet reported George Washington University 31 participants Est. completion 2019-12 1 site

Type 2 diabetes Other conditions: Impaired Renal Function
View official trial listing →
Completed NCT NCT02489968

Linagliptin as Add on Therapy to Empagliflozin 10 mg or 25 mg With Japanese Patients With Type 2 Diabetes Mellitus

Not yet reported Boehringer Ingelheim 880 participants Est. completion 2017-06-16 83 sites Stand-alone

Type 2 diabetes
View official trial listing →
Status unknown NCT NCT02528019

Metabolic and Cardiovascular Effects of Dipeptidyl Peptidase-4 (DPP-4) or Sodium-glucose Co-transporter Type 2 (SGLT2) Inhibitors

Not yet reported Kurume University 100 participants Est. completion 2018-08 1 site

Other conditions: Effects of the DPP-4 Inhibitors or SGLT2 Inhibitors on the Protective Actions for Diabetic Complications
View official trial listing →
Completed NCT NCT02608177

Continuous Glucose Monitoring to Assess Glycemia in Chronic Kidney Disease - Changing Glucose Management

Not yet reported University of Washington 3 participants Est. completion 2018-08 1 site Stand-alone

Chronic kidney diseaseType 2 diabetes
View official trial listing →
Status unknown NCT NCT02725502

Incretin Axis in Type 1 Diabetes Mellitus

Not yet reported Post Graduate Institute of Medical Education and Research, Chandigarh 20 participants Est. completion 2016-05 1 site

Other conditions: Type 1 Diabetes Mellitus
View official trial listing →
Completed NCT NCT02752113

Effects of Empagliflozin + Linagliptin vs Metformin + Insulin Glargine on Renal and Vascular Changes in Type 2 Diabetes

Not yet reported Institut für Pharmakologie und Präventive Medizin 101 participants Est. completion 2019-05 1 site

Type 2 diabetes
View official trial listing →
Completed NCT NCT02758171

Bioequivalence of a Fixed Dose Combination Tablet of Empagliflozin/Linagliptin Compared With the Free Combination of Empagliflozin Tablet and Linagliptin Tablet in Healthy Male and Female Subjects

Not yet reported Boehringer Ingelheim 56 participants Est. completion 2016-08-03 1 site Stand-alone

Other conditions: Healthy
View official trial listing →
Withdrawn NCT NCT02768220

The Effect of Sodium-Glucose Cotransporter 2 Inhibitors on Advanced Glycation End Products

Not yet reported Northwell Health Est. completion 2018-12 Stand-alone

Other conditions: SGLT-2 Inhibitors, Advanced Glycation End Products, Diabetes
View official trial listing →
Completed NCT NCT02792400

The Role of Glucagon in the Effects of Dipeptidyl Peptidase-4 Inhibitors and Sodium-glucose Co-transporter-2 Inhibitors

Not yet reported University Hospital, Gentofte, Copenhagen 24 participants Est. completion 2018-07 1 site

Type 2 diabetes
View official trial listing →
Completed NCT NCT02815644

Empa/Lina FDC Food Effect Study (Japan)

Not yet reported Boehringer Ingelheim 22 participants Est. completion 2016-10-05 1 site Stand-alone

Other conditions: Healthy
View official trial listing →
Completed NCT NCT02821910

Relative Bioavailability of 2 Fixed Dose Combinations of Empagliflozin/Linagliptin/Metformin Extended Release Compared With Single Tablets

Not yet reported Boehringer Ingelheim 50 participants Est. completion 2016-10-31 1 site Stand-alone

Other conditions: Healthy
View official trial listing →
Completed NCT NCT02851745

Effects of Linagliptin on Left Ventricular Myocardial DYsfunction in Patients With Type 2 DiAbetes Mellitus and Concentric Left Ventricular Geometry

Not yet reported Heart Care Foundation 188 participants Est. completion 2019-07-02 19 sites Stand-alone

Type 2 diabetes Other conditions: Left Ventricular Systolic Dysfunction
View official trial listing →
Completed NCT NCT02857946

Bioequivalence Study of Linagliptin From Prevaglip 5 mg Tablets(Eva Pharma, Egypt) and Trajenta 5 mg Tablets (Boehringer Ingelheim International GmbH, Germany)

Not yet reported Genuine Research Center, Egypt 24 participants Est. completion 2016-04 1 site Stand-alone

Other conditions: Healthy
View official trial listing →
Completed NCT NCT02897349

Linagliptin Add-on to Insulin Background Therapy

Not yet reported Boehringer Ingelheim 206 participants Est. completion 2019-01-18 25 sites Stand-alone

Type 2 diabetes
View official trial listing →
Completed NCT NCT02974504

Phase IV Clinical Trial to Investigate the Effect on Blood Glucose of Evogliptin in Patients With Type 2 Diabetes(EVERGREEN)

Not yet reported Dong-A ST Co., Ltd. 207 participants Est. completion 2018-03 1 site Stand-alone

Type 2 diabetes
View official trial listing →
Completed NCT NCT03004612

Effect of Linagliptin + Metformin vs Metformin Alone in Patients With Prediabetes

Not yet reported Universidad de Guanajuato 144 participants Est. completion 2019-06 1 site Stand-alone

Other conditions: Prediabetic State, Insulin Resistance
View official trial listing →
Completed NCT NCT03011177

Teneligliptin Versus Linagliptin in Diabetes Mellitus Type Two Patients

Not yet reported Handok Inc. 168 participants Est. completion 2018-09 1 site

Type 2 diabetes
View official trial listing →
Completed NCT NCT03014479

Study of the QOL Evaluation of Trelagliptin in Patients With Type 2 Diabetes Mellitus

Not yet reported Takeda 219 participants Est. completion 2017-10-21 27 sites

Type 2 diabetes
View official trial listing →
Status unknown NCT NCT03051243

Safety and Efficiency of Linagliptin (Trajenta) in the Setting of Internal Medicine Department

Not yet reported Rabin Medical Center 60 participants Est. completion 2019-11-01

Other conditions: DM2
View official trial listing →
Completed NCT NCT03194945

Effects of Sequential Treatment Based on Lina/MET After Short-term Intensive Insulin in Newly Diagnosed Type 2 Diabetes

Not yet reported Sun Yat-sen University 412 participants Est. completion 2022-12-31 1 site

Type 2 diabetes
View official trial listing →
Status unknown NCT NCT03222765

Prevention of Microvascular Complications in Prediabetes e-PREDICE Study

Not yet reported Evidem Consultores SL 1000 participants Est. completion 2019-12-31 1 site Stand-alone

Prediabetes
View official trial listing →
Completed NCT NCT03250052

A Clinical Trial to Evaluate Pharmacokinetic Interactions and Safety Between Fimasartan and Linagliptin in Healthy Male Volunteers

Not yet reported Boryung Pharmaceutical Co., Ltd 39 participants Est. completion 2017-11-21 1 site Stand-alone

Other conditions: Hypertension
View official trial listing →
Completed NCT NCT03259490

This Study Tests Whether Taking the Medicines Empagliflozin, Linagliptin, and Metformin Together in 1 Pill is the Same as Taking Them in Separate Pills. The Study is Done in Healthy Men and Women and Measures the Amount of Each Medicine in the Blood

Not yet reported Boehringer Ingelheim 30 participants Est. completion 2017-11-13 1 site Stand-alone

Other conditions: Healthy
View official trial listing →
Terminated NCT NCT03281369

A Study of Multiple Immunotherapy-Based Treatment Combinations in Patients With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Cancer (G/GEJ) or Esophageal Cancer (Morpheus-Gastric and Esophageal Cancer)

Not yet reported, Not yet reported Hoffmann-La Roche 219 participants Est. completion 2025-10-09 28 sites Stand-alone

Other conditions: Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma or Esophageal Carcinoma
View official trial listing →
Status unknown NCT NCT03320031

A Study of Adding Linagliptin to Control Glycemic Variability and HbA1c in Peritoneal Dialysis Patients With Type 2 Diabetes(PDPD) With Premixed Insulin Therapy

Not yet reported Yanbing Li 232 participants Est. completion 2019-12 1 site Stand-alone

Type 2 diabetes Other conditions: Peritoneal Dialysis
View official trial listing →
Terminated NCT NCT03337698

A Study Of Multiple Immunotherapy-Based Treatment Combinations In Participants With Metastatic Non-Small Cell Lung Cancer (Morpheus- Non-Small Cell Lung Cancer)

Not yet reported, Not yet reported Hoffmann-La Roche 314 participants Est. completion 2025-11-25 29 sites Stand-alone

Other conditions: Carcinoma, Non-Small-Cell Lung
View official trial listing →
Completed NCT NCT03338803

Real World Glycemic Effectiveness of Linagliptin

Boehringer Ingelheim 11001 participants Est. completion 2018-02-02 1 site

Type 2 diabetes
View official trial listing →
Completed NCT NCT03429543

Diabetes Study of Linagliptin and Empagliflozin in Children and Adolescents (DINAMO)TM

Not yet reported Boehringer Ingelheim 175 participants Est. completion 2023-05-31 83 sites Stand-alone

Type 2 diabetes
View official trial listing →
Status unknown NCT NCT03433248

Renal Actions of Combined Empagliflozin and LINagliptin in Type 2 diabetES

Not yet reported M.H.H. Kramer 66 participants Est. completion 2022-09-01 1 site Stand-alone

Type 2 diabetes
View official trial listing →
Status unknown NCT NCT03458715

The Efficacy of Sodium-glucose Co-transporter 2 Inhibitor or Dipeptidyl Peptidase-4 Inhibitor in Type 2 Diabetes Patients With Premix Insulin

Not yet reported Mackay Memorial Hospital 120 participants Est. completion 2018-11-21 1 site Stand-alone

Type 2 diabetes
View official trial listing →
Completed NCT NCT03470454

Contrast Nephropathy in Type 2 Diabetes

Fayoum University 40 participants Est. completion 2018-11-30 2 sites

Other conditions: Kidney Function Affection Upon Exposure to Radiocontrast, Diabetes, Microalbuminuria
View official trial listing →
Completed NCT NCT03492580

A Study for Comparison of Canagliflozin Versus Alternative Antihyperglycemic Treatments on Risk of Heart Failure Hospitalization and Amputation for Participants With Type 2 Diabetes Mellitus and the Subpopulation With Established Cardiovascular Disease

Janssen Research & Development, LLC 714582 participants Est. completion 2018-06-25 1 site

Type 2 diabetesCardiovascular disease
View official trial listing →
Withdrawn NCT NCT03504566

Rotation for Optimal Targeting of Albuminuria and Treatment Evaluation (ROTATE-2)

Not yet reported Steno Diabetes Center Copenhagen Est. completion 2019-06-01 1 site

Chronic kidney disease
View official trial listing →
Status unknown NCT NCT03585777

Compare Serum Klotho Levels in Patients on Oral Antidiabetic Treatment

Fayoum University 90 participants Est. completion 2019-03 1 site

Other conditions: Compare Serum Level of Klotho in Patients on Oral Antidiabetic Treatment
View official trial listing →
Completed NCT NCT03609294

A Clinical Trial to Evaluate the Pharmacokinetics and Safety/Tolerability of Fimasartan and Linagliptin in Healthy Volunteers

Not yet reported Boryung Pharmaceutical Co., Ltd 67 participants Est. completion 2019-06-30 1 site Stand-alone

Other conditions: Hypertension, Diabetes
View official trial listing →
Completed NCT NCT03629054

This Study in Healthy People Tests Whether Taking a Low Strength of Empagliflozin, Linagliptin, and Metformin Together in 1 Pill is the Same as Taking Them in Separate Pills

Not yet reported Boehringer Ingelheim 30 participants Est. completion 2018-11-05 1 site Stand-alone

Other conditions: Healthy
View official trial listing →
Terminated NCT NCT03642184

Efficacy and Safety of Empagliflozin in NODAT

Not yet reported RenJi Hospital 6 participants Est. completion 2019-01-31 1 site

Other conditions: New Onset Diabetes After Transplant, Kidney Transplant; Complications
View official trial listing →
Completed NCT NCT03648424

Prediction of Findings From the Ongoing CAROLINA Trial Using Healthcare Database Analyses

Brigham and Women's Hospital 48262 participants Est. completion 2019-06-01 1 site

Type 2 diabetes
View official trial listing →
Completed NCT NCT03667300

Effect of Evogliptin on Albuminuria in Patients With Type 2 Diabetes and Renal Insufficiency

Not yet reported Samsung Medical Center 209 participants Est. completion 2019-05-14 1 site

Type 2 diabetes Other conditions: Albuminuria, Renal Insufficiency
View official trial listing →
Withdrawn NCT NCT03766750

Efficacy and Safety of Lima Association in the Control of Type II Diabetes Mellitus.

Not yet reported EMS Est. completion 2023-11

Type 2 diabetes
View official trial listing →
Completed NCT NCT03807440

DIA_CENTRAL:T2D Treatment Pattern in Central Europe

Boehringer Ingelheim 4083 participants Est. completion 2021-08-31 177 sites

Type 2 diabetes
View official trial listing →
Completed NCT NCT03918148

Gliflozins and Cardiovascular Risk Factors in Type 2 Diabetes (GIOIA)

University of Campania Luigi Vanvitelli 1150 participants Est. completion 2023-12-31 1 site

Type 2 diabetes
View official trial listing →
Completed NCT NCT03936036

Replication of the CARMELINA Diabetes Trial in Healthcare Claims

Brigham and Women's Hospital 101830 participants Est. completion 2021-02-18 1 site Added to GLP-1

Other conditions: Diabetes
View official trial listing →
Completed NCT NCT03939624

Sodium-glucose Cotransporter 2 (SGLT2) Inhibitors and Risk of Cardiovascular Events

Canadian Network for Observational Drug Effect Studies, CNODES 419734 participants Est. completion 2019-10-01 1 site

Type 2 diabetesCardiovascular diseaseHeart failure Other conditions: Cardiovascular Death, All-Cause Mortality
View official trial listing →
Completed NCT NCT03970668

Linagliptin in Post-renal Transplantation

Universidad de Guanajuato 28 participants Est. completion 2019-04-30

Other conditions: Transplanted Kidney Complication
View official trial listing →
Status unknown NCT NCT03986073

Study of TQ-F3083 Capsules in Subjects With Type 2 Diabetes Mellitus

Not yet reported Chia Tai Tianqing Pharmaceutical Group Co., Ltd. 120 participants Est. completion 2020-09-30 9 sites Stand-alone

Type 2 diabetes
View official trial listing →
Completed NCT NCT04017221

Safety of Sodium-glucose Cotransporter 2 (SGLT2) Inhibitors Among Patients With Type 2 Diabetes

Canadian Network for Observational Drug Effect Studies, CNODES 1249636 participants Est. completion 2019-12-01 1 site

Type 2 diabetes Other conditions: Urosepsis, Diabetic Ketoacidosis, Lower Extremity Amputation
View official trial listing →
Completed NCT NCT04088461

Effect of Linagliptin + Metformin on Patients Who do Not Achieve Normoglucemia With Metformine

Not yet reported Universidad de Guanajuato 31 participants Est. completion 2018-09 1 site Stand-alone

Prediabetes Other conditions: Prediabetic State, Insulin Resistance
View official trial listing →
Status unknown NCT NCT04131582

Effect of Empagliflozin + Linagliptin + Metformin + Lifestyle in Patients With Prediabetes

Not yet reported Universidad de Guanajuato 34 participants Est. completion 2020-12-30 1 site Stand-alone

Other conditions: Prediabetic State, Insulin Resistance
View official trial listing →
Status unknown NCT NCT04134650

Effect of Low Dose Combination of Linagliptin + Metformin to Prevent Diabetes

Not yet reported Universidad de Guanajuato 34 participants Est. completion 2020-07-01 1 site Stand-alone

Other conditions: Prediabetic State, Insulin Resistance
View official trial listing →
Terminated NCT NCT04180813

Real-world Study Comparing the Adherence and Effectiveness of Linagliptin vs. Acarbose

Boehringer Ingelheim 85 participants Est. completion 2021-07-11 10 sites

Type 2 diabetes
View official trial listing →
Withdrawn NCT NCT04341935

Effects of DPP4 Inhibition on COVID-19

Not yet reported University of Miami Est. completion 2021-12-30 1 site Stand-alone

Type 2 diabetes Other conditions: Coronavirus Infection
View official trial listing →
Terminated NCT NCT04371978

Efficacy and Safety of Dipeptidyl Peptidase-4 Inhibitors in Diabetic Patients With Established COVID-19

Not yet reported Rabin Medical Center 64 participants Est. completion 2021-05-04 3 sites Stand-alone

Type 2 diabetes Other conditions: COVID 19, Coronavirus, Diabetes Mellitus, Glucose Metabolism Disorders, Metabolic Disease, Endocrine System Diseases, Dipeptidyl-Peptidase IV Inhibitors, Linagliptin, Severe Acute Respiratory Syndrome Coronavirus 2, Sars-CoV2, Hypoglycemic Agents, Respiratory Tract Diseases, Incretins, Hormones
View official trial listing →
Completed NCT NCT04542213

Dipeptidyl Peptidase-4 Inhibitor (DPP4i) for the Control of Hyperglycemia in Patients With COVID-19

Not yet reported Hospital Regional de Alta Especialidad del Bajio 70 participants Est. completion 2021-02-28 1 site Stand-alone

Other conditions: Hyperglycemia, Covid19
View official trial listing →
Completed NCT NCT04564872

HSK7653 Metformin Add-on Study in Patients With Type 2 Diabetes Mellitus

Not yet reported Sichuan Haisco Pharmaceutical Group Co., Ltd 465 participants Est. completion 2022-08-29 2 sites Stand-alone

Type 2 diabetes
View official trial listing →
Status unknown NCT NCT04662866

Effects of Glucose Lowering Agents in South Asian Women With Impaired Glucose Tolerance or Impaired Fasting Glucose

Not yet reported Oslo University Hospital 64 participants Est. completion 2023-10 1 site

Prediabetes Other conditions: Insulin Sensitivity, Glucose Metabolism Disorders
View official trial listing →
Completed NCT NCT04735042

SGLT-2 and DPP-4 Inhibition, Subclinical Inflammation of the Genito-urinary Tract and Risk of Infections.

University of Pisa 60 participants Est. completion 2022-04-07 1 site

Type 2 diabetes Other conditions: Urinary Tract Infections
View official trial listing →
Status unknown NCT NCT04796428

GliflOzin in eLderly Diabetic patiENts: A praGmatic Intraclass Evaluation Trial

Not yet reported Center for Outcomes Research and Clinical Epidemiology, Italy 1167 participants Est. completion 2023-12-31

Type 2 diabetes
View official trial listing →
Status unknown NCT NCT04853615

SGLT2 Inhibitors Prophylaxis Against Post-contrast Acute Kidney Injury in Diabetic Kidney Disease?

Fayoum University 800 participants Est. completion 2024-08-01

Other conditions: SGLT2i Kideny Protection Against Contrast in Diabetic Kidney
View official trial listing →
Completed NCT NCT04970940

The Drug-drug Interaction Study of AJU-A51R1 and AJU-A51R2

Not yet reported AJU Pharm Co., Ltd. 30 participants Est. completion 2020-12-31 1 site

Type 2 diabetes
View official trial listing →
Completed NCT NCT04972539

Evaluation of Pharmacokinetics and Safety of AJU-A51 in Healthy Adults

Not yet reported AJU Pharm Co., Ltd. 48 participants Est. completion 2021-03-09 1 site Stand-alone

Type 2 diabetes
View official trial listing →
Status unknown NCT NCT05032001

ORAL ANTIDIABETICS EFFECT ON VISCERAL FAT

Not yet reported Metabolic Research Unit 30 participants Est. completion 2022-08-01 1 site Stand-alone

Type 2 diabetes Other conditions: Abdominal Obesity
View official trial listing →
Completed NCT NCT05066516

The Pharmacokinetics, Safety and Tolerability of IN-C009 in Healthy Subjects

Not yet reported Korea University Anam Hospital 48 participants Est. completion 2020-10-18 1 site Stand-alone

Other conditions: Diabetes Mellitus
View official trial listing →
Completed NCT NCT05073692

Comparison of Type 2 Diabetes Pharmacotherapy Regimens

Kaiser Permanente 241981 participants Est. completion 2025-03-12 6 sites

Type 2 diabetesCardiovascular disease
View official trial listing →
Completed NCT NCT05130463

Esgliteo Post Marketing Surveillance (PMS) in Korean Patients With Type 2 Diabetes Mellitus

Boehringer Ingelheim 1053 participants Est. completion 2024-07-08 30 sites

Type 2 diabetes
View official trial listing →
Status unknown NCT NCT05161429

BESTMED: Observational Evaluation of Second Line Therapy Medications in Diabetes

Brigham and Women's Hospital 550000 participants Est. completion 2024-06-30 5 sites

Type 2 diabetes
View official trial listing →
Status unknown NCT NCT05200793

Efficacy of Empagliflozin or Linagliptin as an Alternative to Metformin for Treatment of Polycystic Ovary Syndrome

Not yet reported Alexandria University 75 participants Est. completion 2022-09-01 1 site

Other conditions: Polycystic Ovary Syndrome (PCOS)
View official trial listing →
Active, not recruiting NCT NCT05220917

Comparative Effectiveness and Safety of Four Second Line Pharmacological Strategies in Type 2 Diabetes Study

Brigham and Women's Hospital 781430 participants Est. completion 2027-09-30 1 site

Type 2 diabetes Other conditions: Cardiovascular Events, Renal Disease
View official trial listing →
Completed NCT NCT05290506

Linagliptin Response to OGTT in Prediabetes and Type 2 Diabetes Mellitus

Not yet reported National University of Malaysia 50 participants Est. completion 2021-03-01 1 site

PrediabetesType 2 diabetes
View official trial listing →
Completed NCT NCT05313529

LIGHT-MCI Trial: GLP-1 Agonist, SGLT2 Inhibitor, and DPP-4 Inhibitor for MCI Remission in Type 2 Diabetes

Not yet reported The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School 396 participants Est. completion 2026-07-01 5 sites Stand-alone

Type 2 diabetes Other conditions: Mild Cognitive Impairment
View official trial listing →
Status unknown NCT NCT05347459

Cognitive Protective Effect of Newer Antidiabetic Drugs

Alexandria University 100 participants Est. completion 2023-12 1 site

Type 2 diabetes
View official trial listing →
Status unknown NCT NCT05641337

Research on Optimal Strategy of Hypoglycemic Therapy for Cirrhosis With Diabetes

Not yet reported Huashan Hospital 184 participants Est. completion 2025-12-30 1 site Stand-alone

Other conditions: Liver Cirrhosis, Diabetes
View official trial listing →
Status unknown NCT NCT05703984

A Study to Evaluate the Safety, PK of GC2129A in Healthy Volunteers Under Fasting Conditions

Not yet reported GC Biopharma Corp 50 participants Est. completion 2023-04-19 1 site Stand-alone

Other conditions: Healthy Volunteers
View official trial listing →
Status unknown NCT NCT05729386

A Study to Evaluate the Safety, PK of GC2129A in Healthy Volunteers Under Fed Conditions

Not yet reported GC Biopharma Corp 34 participants Est. completion 2023-04-17 1 site Stand-alone

Other conditions: Healthy Volunteers
View official trial listing →
Completed NCT NCT05768945

Data Analysis for Drug Repurposing for Effective Alzheimer's Medicines (DREAM)- Semaglutide v DPP4 Inhibitors

Brigham and Women's Hospital 742670 participants Est. completion 2023-12-31 1 site

Other conditions: Diabetes
View official trial listing →
Status unknown NCT NCT05870462

Semaglutide and Vascular Regeneration

Not yet reported Canadian Medical and Surgical Knowledge Translation Research Group 100 participants Est. completion 2024-12 2 sites Added to GLP-1

Cardiovascular diseaseType 2 diabetes Other conditions: Atherosclerosis, Obesity
View official trial listing →
Completed NCT NCT05874167

A Pharmacokinetic Study of DW6013 (FDC of Linagliptin and Metformin) in Healthy Adult Volunteers

Not yet reported Dong Wha Pharmaceutical Co. Ltd. 50 participants Est. completion 2022-10-11 1 site Stand-alone

Other conditions: Healthy Subjects
View official trial listing →
Completed NCT NCT05874180

A Pharmacokinetic Study of DW6013 (FDC of Linagliptin and Metformin) in Healthy Adult Volunteers in Fed Condition

Not yet reported Dong Wha Pharmaceutical Co. Ltd. 31 participants Est. completion 2023-02-03 1 site Stand-alone

Other conditions: Healthy Subjects
View official trial listing →
Not yet recruiting NCT NCT05886088

Efficacy and Safety of LID104 in the Treatment of Type II Diabetes Mellitus

Not yet reported EMS 597 participants Est. completion 2027-01 1 site Stand-alone

Type 2 diabetes
View official trial listing →
Completed NCT NCT05956522

Bioequivalence Study of Empagliflozin And Linagliptin Tablets in Healthy Chinese Subjects

Not yet reported The Affiliated Hospital of Qingdao University 106 participants Est. completion 2023-01-13 1 site Stand-alone

Other conditions: Healthy
View official trial listing →
Status unknown NCT NCT06098625

Empagliflozin Versus Linagliptin in Renal Ransplant Recipients With Diabetes Mellitus

Not yet reported Medanta, The Medicity, India 200 participants Est. completion 2025-12-01

Other conditions: Diabetes Mellitus, Kidney Transplant; Complications
View official trial listing →
Status unknown NCT NCT06243809

The Bioequivalence Study of Linagliptin 5 mg Film-coated Tablet in Healthy Thai Volunteers

Not yet reported International Bio service 48 participants Est. completion 2024-07-02 Stand-alone

Other conditions: Healthy Volunteer
View official trial listing →
Status unknown NCT NCT06449235

Real-World Evaluation of Omarigliptin for Type 2 Diabetes Meliitus in Bangladesh

Not yet reported Bangladesh Institute of Research and Rehabilitation in Diabetes, Endocrine and Metabolic Disorders 938 participants Est. completion 2025-06 1 site

Other conditions: Type2diabetes
View official trial listing →
Status unknown NCT NCT06570980

Comparative Analysis of Cost-effectiveness Between Sulfonylureas and DPP4 Inhibitors in Combination With Metformin in Treatment of Type 2 Diabetic Patients : A Retrospective, Observational Study.

Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh 200 participants Est. completion 2024-08-30 1 site

Type 2 diabetes
View official trial listing →
Completed NCT NCT06851962

Impact of Pharmacogenetic-Guided Treatment on Type 2 Diabetes.

Not yet reported Fundación para la Investigación del Hospital Clínico de Valencia 92 participants Est. completion 2026-06-30 3 sites Added to GLP-1

Type 2 diabetes
View official trial listing →
Completed NCT NCT06932159

Bioequivalence Study to Compare Empagliflozin + Linagliptin 25 mg/5 mg Film-coated Tablets Versus Glyxambi 25 mg/ 5 mg Film-coated Tablets

Not yet reported Humanis Saglık Anonim Sirketi 40 participants Est. completion 2025-04-08 1 site Stand-alone

Type 2 diabetes
View official trial listing →
Not yet recruiting NCT NCT06946628

New Triple Therapy in Newly Diagnosed Type 2 Diabetes

Not yet reported Sun Yat-sen University 296 participants Est. completion 2030-12-31 1 site

Other conditions: Diabetes Mellitus
View official trial listing →
Not yet recruiting NCT NCT07034781

A Study to Evaluate the Safety and Pharmacokinetics of Dapagliflozin, Linagliptin, and Metformin in Healthy Adults

Not yet reported AJU Pharm Co., Ltd. 50 participants Est. completion 2025-11 1 site Stand-alone

Type 2 diabetes
View official trial listing →
Completed NCT NCT07039890

To Compare and Evaluate the Oral Bioavailability of Empagliflozin + Linagliptin 10 mg/5 mg Filmcoated Tablets With That of Glyxambi 10 mg/ 5 mg Film-coated Tablets in Healthy, Adult, Human Subjects Under Fasting Conditions.

Not yet reported Humanis Saglık Anonim Sirketi 40 participants Est. completion 2025-06-05 1 site Stand-alone

Type 2 diabetes
View official trial listing →
Not yet recruiting NCT NCT07044765

A Study to Evaluate the Safety and Pharmacokinetics of Dapagliflozin, Linagliptin, and Metformin in Healthy Adults: Fed State Study

Not yet reported AJU Pharm Co., Ltd. 32 participants Est. completion 2025-11 1 site Stand-alone

Type 2 diabetes
View official trial listing →
Active, not recruiting NCT NCT07188545

Using Secondary Data to Evaluate Sex-based Heterogeneity of GLP-1 Agonists and SGLT2 Inhibitors on Cardiovascular-Kidney-Metabolic Health (CKMH) Outcomes in Real-world Settings (DASH-CKMH)

Ohio State University 23280000 participants Est. completion 2029-06-30 1 site

Metabolic syndrome
View official trial listing →
Not yet recruiting NCT NCT07198932

Cofrogliptin and Linagliptin as add-on Therapy to Insulin in Type 2 Diabetes

Yanbing Li 594 participants Est. completion 2027-12-31 7 sites

Type 2 diabetes
View official trial listing →
Completed NCT NCT07213895

Bioequivalence Study to Compare Empagliflozin/Linagliptin/Metformin HCL 25mg/5mg/1000mg Extended-Release Tablets Versus Trijardy® XR Extended Release Film Coated Tablets

Not yet reported Humanis Saglık Anonim Sirketi 14 participants Est. completion 2025-09-18 1 site Stand-alone

Type 2 diabetes
View official trial listing →
Completed NCT NCT07247656

The Efficacy and Safety of Empagliflozin - Linagliptin and Empagliflozin- Metformin Therapy in Reduction of Body Weight in Type 2 Diabetic Patients .

Not yet reported Bahria University 200 participants Est. completion 2023-05-01 1 site

Other conditions: Diabete Mellitus
View official trial listing →
Enrolling by invitation NCT NCT07452913

Metformin, Empagliflozin With Sitagliptin vs Linagliptin in Type 2 Diabetes

Not yet reported Bahria University 110 participants Est. completion 2026-06-30 1 site

Type 2 diabetes
View official trial listing →
Not yet recruiting NCT NCT07635953

New Triple Combination Therapy in Newly Diagnosed Type 2 Diabetes

Not yet reported Sun Yat-sen University 296 participants Est. completion 2031-07-01 1 site

Other conditions: Diabetes Mellitus
View official trial listing →
Withdrawn NCT NCT07677865

GLP-1 Receptor Agonists and Alzheimer's Disease: A Multi-National Target Trial Emulation

West China Hospital Est. completion 2026-06-24 1 site

Type 2 diabetes Other conditions: Alzheimer Disease, Obesity & Overweight
View official trial listing →
Completed NCT NCT07691203

Bioequivalence Study to Compare Empagliflozin/Linagliptin/Metformin HCl 25 mg/5 mg/1000 mg Extended Release Tablet Versus Trijardy® XR 25 mg/5 mg/1000 mg Extended- Release Tablets

Not yet reported Humanis Saglık Anonim Sirketi 36 participants Est. completion 2026-07-01 1 site Stand-alone

Type 2 diabetesCardiovascular disease
View official trial listing →
Withdrawn NCT NCT07786571

Study on Improving Blood Glucose Homeostasis With Dorzagliatin Tablets in the Treatment of Type 2 Diabetes Mellitus Patients With Moderate to Severe Chronic Renal Insufficiency

Not yet reported Sun Yat-sen University Est. completion 2029-07-01 1 site

Type 2 diabetesChronic kidney disease Other conditions: Chronic Renal Insufficiency, Glucose Homeostasis
View official trial listing →
Not yet recruiting NCT NCT07852546

Cardioprotection Effect of Linagliptin

Not yet reported Tanta University 140 participants Est. completion 2028-12-31 1 site Stand-alone

Other conditions: Cardiotoxicity
View official trial listing →
Completed NCT NCT07872358

Bioequivalence Study to Compare Empagliflozin/Linagliptin/Metformin HCl25 mg/5 mg/1000 mg Extended Release Tablet Versus Trijardy® XR 25 mg/5 mg/1000 mg Extended- Release Tablets

Not yet reported Humanis Saglık Anonim Sirketi 36 participants Est. completion 2026-10-07 1 site Stand-alone

Type 2 diabetesCardiovascular disease
View official trial listing →

Efficacy history

Not yet reported.

Safety

Not yet reported.

Sources

ClinicalTrials.gov — NCT07786571

Also known as: Linagliptin, Linagliptin and metformin hydrochloride

Related On The Pen coverage

No related coverage yet.

This drug may be investigational and not yet approved for any use. Whether someone can join a clinical trial is determined only by that trial's own study team — On The Pen does not determine eligibility. Information here can change; always confirm current details on the official ClinicalTrials.gov listing or with the sponsor.